Key Highlights

  • Q3 2026 Revenue reached a record $211 million, up 58% year over year.
  • U.S. glaucoma revenue rose 47% and corneal health sales grew 154%.
  • Adjusted EPS came in at $0.47, compared with a loss of $0.16 a year earlier, as gross Margin widened to 85%.
  • Full year 2026 revenue guidance raised to $775 million to $785 million, with preliminary 2027 revenue projected at $1 billion.

Record Quarter Driven by Two Product Categories

Glaukos reported third quarter 2026 revenue of $211 million, a record for the company and a 58% increase from the prior year period. The growth was broad based, led by a 47% rise in U.S. glaucoma revenue and a 154% jump in corneal health sales. Profitability improved sharply alongside the top line, with adjusted Earnings Per Share of $0.47 compared with a loss of $0.16 in the year ago quarter, and gross margin expanding to 85%.

Guidance Raised on iDose TR and Epioxa Rollouts

Management increased full year 2026 revenue guidance to a range of $775 million to $785 million, up from a prior range of $680 million to $700 million, reflecting confidence in the current pace of adoption. Looking further ahead, the company issued a preliminary 2027 revenue projection of $1 billion, citing continued rollouts of iDose TR and Epioxa as key growth drivers that should extend the company's momentum into next year. Glaukos ended the quarter with $339.8 million in cash and no outstanding debt, giving it flexibility to continue funding commercial expansion and new product launches without relying on external financing.

What drove Glaukos's record Q3 2026 revenue?

Revenue growth was driven by a 47% increase in U.S. glaucoma revenue and a 154% increase in corneal health sales, pushing total revenue to $211 million, up 58% year over year.

What is Glaukos's updated guidance for 2026 and 2027?

Glaukos raised full year 2026 revenue guidance to $775 million to $785 million and issued a preliminary 2027 revenue projection of $1 billion.